| Abstract: | Nearly 95 percent of the world demand for molybdenum-99 (Mo-99)—perhaps the world's most important medical isotope—is met by just four manufacturers, all of whom use highly enriched uranium (HEU) targets in their isotope production programs. Research and development on the use of low-enriched uranium targets and gel generators to produce Mo-99 began in the 1980s; some success has been achieved, but Mo-99 is still mainly produced by irradiating HEU targets in a reactor. Fission-produced Mo-99 has a high specific activity, but activation methods provide low specific activity Mo-99, which is unsuitable for the generators routinely used in most of the world's medical centers. This article evaluates the use of enriched Mo-98 to produce Mo-99 by activation methods; the use of medium specific activity Mo-99 for the preparation of alumina-based generators is also discussed. This article concludes that if support is provided for the production of enriched Mo-98, it may replace to a significant extent the use of HEU and LEU for the production of Mo-99. |
